- Exploring the nexus between obesity, metabolic syndrome, and colorectal cancer
-
Jong Yoon Lee
-
Kosin Med J. 2024;39(1):18-25. Published online March 12, 2024
-
DOI: https://doi.org/10.7180/kmj.24.107
-
-
1,974
View
-
50
Download
-
1
Citations
-
 Abstract
 PDF PubReader  ePub
- The increasing global prevalence of obesity and metabolic syndrome (MetS) is strongly associated with the incidence of colorectal cancer (CRC). Obesity and MetS detrimentally impact the treatment outcomes of CRC and share similar mechanisms that contribute to the development of CRC. Increased insulin resistance in patients with obesity is linked to CRC, and altered levels of sex hormones and adipokines affect cell growth and inflammation. Obesity and MetS also alter the gut microbiome. Bile acids, which are crucial for lipid metabolism, are elevated in patients with obesity. Moreover, specific bile acids are associated with colonic damage, inflammation, and the development of CRC. Obesity and MetS increase the risk of postoperative complications and affect the response to chemotherapy. The promotion of weight loss and the resolution of MetS can reduce the occurrence of CRC and increase treatment efficacy. Therefore, it is imperative to implement appropriate management strategies to address obesity and MetS with the aim of improving the prognosis and reducing the incidence of CRC. Moreover, additional research should be conducted to determine the optimal timing for tailored CRC screening in patients with obesity or MetS. In this review, we explore the impact of obesity and MetS on the development of CRC and examine potential strategies to mitigate CRC risk in individuals with obesity and MetS.
-
Citations
Citations to this article as recorded by  - Colorectal Cancer and Obesity
Hyeong Ho Jo
Journal of Digestive Cancer Research.2024; 12(2): 82. CrossRef
- Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report
-
Minna Kim, Jong Hoon Lee, Jong Yoon Lee
-
Kosin Med J. 2023;38(4):300-306. Published online July 28, 2023
-
DOI: https://doi.org/10.7180/kmj.23.121
-
-
Abstract
PDFPubReader ePub
- Drug-induced immune thrombocytopenia (DITP) is a very rare disease, with an estimated annual incidence of 10 cases per million. Oxaliplatin and irinotecan are widely used as chemotherapy for high-risk stage II and III colorectal cancer, and DITP has been reported to occur in patients using those agents. To treat unresectable metastatic colorectal cancer, bevacizumab is used in combination with oxaliplatin or irinotecan, and there have been a few reports of DITP cases in patients receiving that regimen. In this report, we describe a 68-year-old male patient with metastatic colon cancer (KRAS mutant type) to the liver and lung who developed acute immune-mediated thrombocytopenia due to bevacizumab-FOLFOX (5-fluorouracil, leucovorin, and oxaliplatin) therapy. During treatment, he showed purpura in his lower extremities on 21st cycle day 2. Lab work revealed a platelet count of less than 2,000/mL, reflecting a decrease from 135,000/mL at the start of the cycle 1 day prior. He did not have any other types of cytopenia or significant changes in laboratory findings. We diagnosed DITP due to bevacizumab-FOLFOX, and the patient did not show isolated thrombocytopenia after switching to Ziv-aflibercept-FOLFIRI (5-fluorouracil, leucovorin, and irinotecan).
|
KOSIN UNIVERSITY COLLEGE OF MEDICINE
